BioSpace News Archive

UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 (intranasal niclosamide) as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.

Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in February and March 2021.

Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis

Aquarius Surgical Technologies Inc. (CSE:ASTI) (“ASTI” or the “Company”) announces that Gordon Willox has been removed as a director of, and from all offices and positions in Surgical Lasers Inc., the wholly-owned operating subsidiary of the Company, with immediate effect.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2020 financial results after the close of market on Thursday, February 25, 2021

ESSA Pharma Inc. (“ESSA”, or the “Company”) (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 4,830,918 of its common shares at a public offering price of $27.00 per share before underwriting discounts (the “Offering”)

The defining challenge of this century will be to meet the energy needs of a global population expected to reach nearly 10 billion by 2050 while slashing the balance of planet-warming greenhouse gases entering the atmosphere to nearly zero.

As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1